文献速递骨肿瘤小儿骨科

基于DNA/RNA临床测序在骨与软组织肉瘤中检测新型酪氨酸激酶融合基因作为潜在治疗靶点

Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
PubMed 文献 · Clin Orthop Relat Res · 2023-11-28

该研究于2017至2020年在五家机构纳入82例骨与软组织肉瘤患者,采用TruSight Tumor 170检测基因改变,RNA筛查在24%(20/82)患者中检出融合基因,在19%(11/58)肿瘤特异性融合阴性肉瘤中检出潜在可用融合,其中9例携带酪氨酸激酶融合基因,5例为框内融合;功能分析显示骨内检出的STRN3-NTRK3在3T3细胞中具强转化潜力且对拉罗替尼敏感,携带LMNA-NTRK1和CLTC-ALK融合的患者经酪氨酸激酶抑制剂临床试验治疗达完全缓解。

要点

  • RNA筛查在24%(20/82)骨与软组织肉瘤患者中检出融合基因。
  • 19%(11/58)肿瘤特异性融合阴性肉瘤检出潜在可用融合,9例携带酪氨酸激酶融合基因。
  • STRN3-NTRK3在3T3细胞中具强转化潜力,阳性细胞体外对拉罗替尼敏感。

核心结论

  • 基于RNA的分析可在骨与软组织肉瘤中识别有用的潜在酪氨酸激酶融合治疗靶点。
  • 在1例骨平滑肌肉瘤患者中成功识别STRN3-NTRK3融合,并通过功能分析和药物效应确定了该融合基因的恶性潜力。
  • 鉴于这些发现,即使肉瘤为骨肉瘤,也应考虑进行全面基因组分析。
  • 当前基于DNA的全面基因组分析检测似乎存在一些局限性,使用RNA检测对正确诊断和准确识别融合基因很重要。

研究设计与样本

  • 2017年至2020年在五家机构治疗100例骨与软组织肉瘤患者,其中90%(90例)符合条件,8%(8例)因失访或诊断改变被排除,最终82%(82例)纳入分析。
  • 纳入82例(8例骨肉瘤和74例软组织肉瘤)患者,使用TruSight Tumor 170检测突变、拷贝数变异和基因融合。
  • 进行体外功能分析以确定所识别酪氨酸激酶融合是否与致癌能力和药物反应相关。
  • 2例携带NTRK融合和ALK融合的儿童患者在临床试验中接受酪氨酸激酶抑制剂治疗。

主要发现

  • 基于DNA的分析检测到TP53以及MDM2和CDK4的拷贝数改变,这些单核苷酸变异和拷贝数变异富集于特定的融合阴性肉瘤。
  • RNA筛查在24%(20/82)患者中检出融合基因。
  • 在19%(11/58)肿瘤特异性融合阴性肉瘤中检出潜在可用融合,其中9例携带酪氨酸激酶融合基因,5例携带框内酪氨酸激酶融合基因(STRN3-NTRK3、VWC2-EGFR、ICK-KDR、FOXP2-MET和CEP290-MET),病理意义未知。
  • 功能分析显示骨内检出的STRN3-NTRK3重排在3T3细胞中具有强转化潜力,STRN3-NTRK3阳性细胞体外对拉罗替尼敏感。

关键数值与推荐

  • RNA筛查在24%(20/82)患者中检出融合基因。
  • 在19%(11/58)肿瘤特异性融合阴性肉瘤中检出潜在可用融合,其中9例携带酪氨酸激酶融合基因。
  • 5例携带框内酪氨酸激酶融合基因:STRN3-NTRK3、VWC2-EGFR、ICK-KDR、FOXP2-MET和CEP290-MET。
  • 携带LMNA-NTRK1和CLTC-ALK融合的患者经酪氨酸激酶抑制剂临床试验治疗达完全缓解。

临床怎么用

  • 作者认为,即使肉瘤为骨肉瘤,也应考虑进行全面基因组分析。
  • 作者认为,当前基于DNA的全面基因组分析检测似乎存在一些局限性,使用RNA检测对正确诊断和准确识别融合基因很重要。
  • 作者认为,DNA和RNA筛查系统可能有助于在特定融合阴性肉瘤中检测酪氨酸激酶融合基因并识别关键治疗靶点。
  • 作者认为,鉴于当前DNA测序会漏检融合基因,RNA筛查系统应作为全球范围的检测被广泛考虑用于肉瘤。
  • 作者认为,如果化疗等标准治疗无效,或即使肉瘤为骨肉瘤,也应考虑RNA测序以识别尽可能多的治疗靶点。

局限性

  • 当前基于DNA的全面基因组分析检测似乎存在一些局限性。
  • 需要对更多患者进行研究、验证结果并对未知酪氨酸激酶融合基因进行进一步功能分析,以建立未来治疗方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 1% of clinically treatable tyrosine kinase fusions, including anaplastic lymphoma kinase, neurotrophic tyrosine receptor kinase, RET proto-oncogene, and ROS proto-oncogene 1, have been identified in soft tissue sarcomas via comprehensive genome profiling based on DNA sequencing. Histologic tumor-specific fusion genes have been reported in approximately 20% of soft tissue sarcomas; however, unlike tyrosine kinase fusion genes, these fusions cannot be directly targeted in therapy. Approximately 80% of tumor-specific fusion-negative sarcomas, including myxofibrosarcoma and leiomyosarcoma, that are defined in complex karyotype sarcomas remain genetically uncharacterized; this mutually exclusive pattern of mutations suggests that other mutually exclusive driver oncogenes are yet to be discovered. Tumor-specific, fusion-negative sarcomas may be associated with unique translocations, and oncogenic fusion genes, including tyrosine kinase fusions, may have been overlooked in these sarcomas. QUESTIONS/PURPOSES: (1) Can DNA- or RNA-based analysis reveal any characteristic gene alterations in bone and soft tissue sarcomas? (2) Can useful and potential tyrosine kinase fusions in tumors from tumor-specific, fusion-negative sarcomas be detected using an RNA-based screening system? (3) Do the identified potential fusion tumors, especially in neurotrophic tyrosine receptor kinase gene fusions in bone sarcoma, transform cells and respond to targeted drug treatment in in vitro assays? (4) Can the identified tyrosine kinase fusion genes in sarcomas be useful therapeutic targets? METHODS: Between 2017 and 2020, we treated 100 patients for bone and soft tissue sarcomas at five institutions. Any biopsy or surgery from which a specimen could be obtained was included as potentially eligible. Ninety percent (90 patients) of patients were eligible; a further 8% (8 patients) were excluded because they were either lost to follow-up or their diagnosis was changed, leaving 82% (82 patients) for analysis here. To answer our first and second questions regarding gene alterations and potential tyrosine kinase fusions in eight bone and 74 soft tissue sarcomas, we used the TruSight Tumor 170 assay to detect mutations, copy number variations, and gene fusions in the samples. To answer our third question, we performed functional analyses involving in vitro assays to determine whether the identified tyrosine kinase fusions were associated with oncogenic abilities and drug responses. Finally, to determine usefulness as therapeutic targets, two pediatric patients harboring an NTRK fusion and an ALK fusion were treated with tyrosine kinase inhibitors in clinical trials. RESULTS: DNA/RNA-based analysis demonstrated characteristic alterations in bone and soft tissue sarcomas; DNA-based analyses detected TP53 and copy number alterations of MDM2 and CDK4 . These single-nucleotide variants and copy number variations were enriched in specific fusion-negative sarcomas. RNA-based screening detected fusion genes in 24% (20 of 82) of patients. Useful potential fusions were detected in 19% (11 of 58) of tumor-specific fusion-negative sarcomas, with nine of these patients harboring tyrosine kinase fusion genes; five of these patients had in-frame tyrosine kinase fusion genes ( STRN3-NTRK3, VWC2-EGFR, ICK-KDR, FOXP2-MET , and CEP290-MET ) with unknown pathologic significance. The functional analysis revealed that STRN3-NTRK3 rearrangement that was identified in bone had a strong transforming potential in 3T3 cells, and that STRN3-NTRK3 -positive cells were sensitive to larotrectinib in vitro. To confirm the usefulness of identified tyrosine kinase fusion genes as therapeutic targets, patients with well-characterized LMNA-NTRK1 and CLTC-ALK fusions were treated with tyrosine kinase inhibitors in clinical trials, and a complete response was achieved. CONCLUSION: We identified useful potential therapeutic targets for tyrosine kinase fusions in bone and soft tissue sarcomas using RNA-based analysis. We successfully identified STRN3-NTRK3 fusion in a patient with leiomyosarcoma of bone and determined the malignant potential of this fusion gene via functional analyses and drug effects. In light of these discoveries, comprehensive genome profiling should be considered even if the sarcoma is a bone sarcoma. There seem to be some limitations regarding current DNA-based comprehensive genome profiling tests, and it is important to use RNA testing for proper diagnosis and accurate identification of fusion genes. Studies on more patients, validation of results, and further functional analysis of unknown tyrosine kinase fusion genes are required to establish future treatments. CLINICAL RELEVANCE: DNA- and RNA-based screening systems may be useful for detecting tyrosine kinase fusion genes in specific fusion-negative sarcomas and identifying key therapeutic targets, leading to possible breakthroughs in the treatment of bone and soft tissue sarcomas. Given that current DNA sequencing misses fusion genes, RNA-based screening systems should be widely considered as a worldwide test for sarcoma. If standard treatments such as chemotherapy are not effective, or even if the sarcoma is of bone, RNA sequencing should be considered to identify as many therapeutic targets as possible.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Hasegawa N, Hayashi T, Niizuma H, et al. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing. Clin Orthop Relat Res. 2023. PMID: 38014853. doi:10.1097/CORR.0000000000002901

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。